Back to mobile site
Get it on Google Play

Zealand Pharma starts Phase 3 trials for obesity drug petrelintide

September 22, 2026 11:00 AM EDT Send to a Friend
Zealand Pharma A/S (Nasdaq: ZEAL) has initiated a global registrational Phase 3 program, called ZUPREME, to evaluate the efficacy and ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE

Member Login